Metastatic Adenocarcinoma Detection on Metastatic adenocarcinoma (MA)
100SensitivityMOC 31
Evaluation results
| Method | Links | ||
|---|---|---|---|
| MOC 31Reference Study=[19]2026.07 | 100 | — | |
| nnU-Net2026.07 | 100 | — | |
| pCEAReference Study=[2], Positive Staining Pattern Definition=membranous and/or cytoplasmic2026.07 | 96 | — | |
| pCEAReference Study=[5], Positive Staining Pattern Definition=membranous and/or cytoplasmic2026.07 | 93 | — | |
| MOC 31Reference Study=[1]2026.07 | 92 | — | |
| MOC 31Reference Study=[5]2026.07 | 85 | — | |
| CK20Reference Study=[20]2026.07 | 74 | — | |
| MOC 31Reference Study=[2]2026.07 | 66 | — | |
| CK19Reference Study=[20]2026.07 | 64 | — | |
| CK7Reference Study=[2]2026.07 | 36 | — | |
| CK20Reference Study=[2]2026.07 | 30 | — | |
| CK19Reference Study=[2]2026.07 | 29 | — | |
| Hep Par 1Reference Study=[2]2026.07 | 14 | — | |
| Hep Par 1Reference Study=[3]2026.07 | 6 | — | |
| GPC3Reference Study=[11]2026.07 | 6 | — | |
| CK7Reference Study=[20]2026.07 | 3 | — | |
| Hep Par 1Reference Study=[1]2026.07 | 2 | — | |
| Hep Par 1Reference Study=[5]2026.07 | 0 | — | |
| GPC3Reference Study=[16]2026.07 | 0 | — |